ORAL SESSIONS Journal of Thoracic Oncology

Slides:

Advertisements

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Advertisements

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

PUBLISH ONLY Journal of Thoracic Oncology

Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma Dean A. Fennell, PhD, FRCP,

E13-01: Insights into thymic epithelial tumor: pathology

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

SC17.02 Lung Cancer in China: Challenges and Perspectives

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer Peter M.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Frank Detterbeck, MD Journal of Thoracic Oncology

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Influence of Apoptosis and Cell Cycle Regulator Proteins on Chemotherapy Response and Survival in Stage IIIA/IIIB NSCLC Patients José L. Morero, MD,

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y.

PUBLISH ONLY Journal of Thoracic Oncology

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Imaging Requirements in the Practice of Pulmonary Metastasectomy

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Erratum Journal of Thoracic Oncology

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Heidi B. Rolke, Frode Gallefoss Journal of Thoracic Oncology

Mitotic Inhibitors Journal of Thoracic Oncology

JCSE01.16 Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

ES Lung Cancer Surgery for High Risk Patients

Extending Surgery for Pulmonary Metastasectomy: What Are the Limits?

A Simple Solution for Complicated Pleural Effusions

MTP13-01: Indications and limitations of bronchoscopy

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Clinical Relevance of Our Multimodality Prognostic Score

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada Marcy Winget, PhD, Jennifer.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Extended Resections for Thymic Malignancies

Genetic Changes in Squamous Cell Lung Cancer: A Review

International Thymic Malignancies Interest Group: A Way Forward

European Lung Cancer Conference (ELCC) 2016 Organisation

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

David James Pinato, MD, MRes, Francesco A

Novel Drugs—Miscellaneous Category

IASLC 6th Latin American Conference on Lung Cancer

Neal S Goldstein, MD The Annals of Thoracic Surgery

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Epidemiology of Thymoma and Associated Malignancies

Induction Therapy For Locally Advanced Thymoma

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Mark A. Socinski, MD Journal of Thoracic Oncology

Presentation transcript:

ORAL SESSIONS Journal of Thoracic Oncology Journal of Thoracic Oncology Volume 10, Issue 9, Pages S173-S260 (September 2015) DOI: 10.1016/S1556-0864(16)30010-7 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Frequency of genomic alterations identified in this study Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Examples of 3D T 1-weighted Pleural MR images acquired 4.5 minutes post-Gadobutrol in 2 different patients – one with BAPE (Panel A) and one with early-stage MPM (Panel B). Panels C and D show the accompanying parietal pleura SI/time curves for each patient (Panel C: patient with BAPE – ECE absent, Panel D: patient with MPM – ECE present) Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 A) Serum cisplatin kinetics over 120 hours and B) Cumulative and pre-dose subtracted AUC0-120 of the 4 dose levels, Data is presented in median with range (n=3 for each dosage group). Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Survival by Surgeon Score Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Examples of lung cancer specimens with concordance of scores by seven pathologists for faint (A), moderate (B) and strong (C) expression of cMET protein by immunohistochemistry (all pictures taken with 40X objective) Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10 Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig 1 Low SMARCA4 correlates with improved disease-specific survival with adjuvant cisplatin-based chemotherapy in the JBR.10 trial. Journal of Thoracic Oncology 2015 10, S173-S260DOI: (10.1016/S1556-0864(16)30010-7) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions